Skip to content

R&D at other companies

CareDx logo
CareDxCDNA
$21.42M+15.6%
Guardant Health logo
Guardant HealthGH
$91.04M+2.8%
Natera, Inc. logo
Natera, Inc.NTRA
$210.7M+63.2%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$14.18M+14.4%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$62.9M-14.4%
Agilent Technologies logo
Agilent TechnologiesA
$126M+12.5%

Other financials

Income statement

See full
Revenue$32.0K-98.5%
Gross profit$15.0K-98.9%
Operating income-$4.4M+35.1%
Net income-$4.3M+35.7%
EPS (diluted)-$0.12+53.8%

Balance sheet

See full
Cash & equivalents$28.2M-9.1%
Total debt$2.9M-13.5%
Total equity-$10.7M-205%
Total assets$40.4M-33.0%

Cash flow

See full
Operating cash flow-$7.6M-30.8%
CapEx$613.0K+99.7%
Free cash flow-$8.3M-34.3%

Valuation

See full
Market cap$185.35M+92.3%
Enterprise value$160.03M+113%
P/S95.1×+72.5×

Profitability

See full
Gross margin51.3%-3.0pp
Operating margin-2,500.7%+4,459pp
Net margin-2,454.6%+4,017pp
FCF margin-1,409.7%-6,023pp

Returns & leverage

See full
Return on equity-532.9%-717pp
Debt / equity2.9×+2.8×
Current ratio2.5×-1.2×

Where this comes from

Reported directly by IMDX in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: IMDX’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about IMDX's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IMDX's R&D?
IMDX (IMDX) reported R&D of $4.95M in Q1 2026.
How has IMDX's R&D changed year-over-year?
IMDX's R&D increased by 69.4% year-over-year, from $2.92M to $4.95M.
What is the long-term trend for IMDX's R&D?
Over 4 years (2021 to 2025), IMDX's R&D has grown at a 3.9% compound annual growth rate (CAGR), from $13.63M to $15.91M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.